Inhibikase Therapeutics (IKT) EBITDA Yield: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$1.98-0.02 (-1.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$261.43M	N/A	N/A	N/A	N/A
X4 Pharmaceuticals, Inc. (XFOR)vs ›	$261.27M	N/A	N/A	N/A	N/A
TriSalus Life Sciences, Inc. (TLSI)vs ›	$262.92M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$259.56M	N/A	55.26%	33.09%	19.40%
Treace Medical Concepts, Inc. (TMCI)vs ›	$259.49M	N/A	0.12%	0.12%	0.12%
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$259.14M	N/A	N/A	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$259.12M	N/A	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$258.63M	N/A	0.00%	0.00%	0.00%
Scribe Therapeutics Inc. (SCTX)vs ›	$264.25M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$265.78M	N/A	10.04%	10.04%	9.67%

NAME

MARKET CAP

EBITDA YIELD

TTM

Inhibikase Therapeutics, Inc. (IKT)

$261.43M

N/A

X4 Pharmaceuticals, Inc. (XFOR)vs ›

$261.27M

N/A

TriSalus Life Sciences, Inc. (TLSI)vs ›

$262.92M

N/A

OraSure Technologies, Inc. (OSUR)vs ›

$259.56M

N/A

55.26%

33.09%

19.40%

Treace Medical Concepts, Inc. (TMCI)vs ›

$259.49M

N/A

0.12%

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$259.14M

N/A

Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›

$259.12M

N/A

Palisade Bio, Inc. (PALI)vs ›

$258.63M

N/A

0.00%

Scribe Therapeutics Inc. (SCTX)vs ›

$264.25M

N/A

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$265.78M

N/A

10.04%

9.67%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

IKT EBITDA Yield Metrics

IKT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics